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Insult-provoked transformation of neuronal networks
into epileptic ones involves multiple mechanisms.
Intervention studies have identified both dysregu-
lated inflammatory pathways and NRSF-mediated
repression of crucial neuronal genes as contributors
to epileptogenesis. However, it remains unclear how
epilepsy-provoking insults (e.g., prolonged seizures)
induce both inflammation and NRSF and whether
common mechanisms exist. We examined miR-124
as a candidate dual regulator of NRSF and inflamma-
tory pathways. Status epilepticus (SE) led to reduced
miR-124 expression via SIRT1—and, in turn, miR-124
repression—via C/EBPa upregulated NRSF. We
tested whether augmenting miR-124 after SE would
abort epileptogenesis by preventing inflammation
and NRSF upregulation. SE-sustaining animals
developed epilepsy, but supplementing miR-124
did not modify epileptogenesis. Examining this result
further, we found that synthetic miR-124 not only
effectively blocked NRSF upregulation and rescued
NRSF target genes, but also augmented microglia
activation and inflammatory cytokines. Thus, miR-
124 attenuates epileptogenesis via NRSF while pro-
moting epilepsy via inflammation.
INTRODUCTION
The transformative mechanisms converting neuronal networks
into epileptic ones (Vezzani et al., 2011; Engel et al., 2013a; Si-
monato et al., 2014) are driven, at least partly, by altered expres-
sion and function of crucial neuronal genes (Brooks-Kayal et al.,
2009; Cacheaux et al., 2009; Goldberg and Coulter, 2013; Ros-
signol et al., 2014), in parallel with activation of inflammatory cells
(Pernot et al., 2011; Vezzani et al., 2011). Recently, interfering
with the repression of numerous target genes by the transcrip-
tional repressor neuron restrictive silencer factor (NRSF) was
found to attenuate the development of epilepsy in the short2402 Cell Reports 14, 2402–2412, March 15, 2016 ª2016 The Authorterm (McClelland et al., 2011), supporting a mechanistic role in
epileptogenesis (Gao et al., 2011; Baldelli and Meldolesi 2015).
In addition, anti-inflammatory strategies have modified the
course of this disease, supporting the contribution of inflamma-
tion to insult-provoked epilepsy (Maroso et al., 2011; Li et al.,
2013). It is unclear how epilepsy-provoking insults, such as
status epilepticus (SE), initiate both NRSF dysregulation and
pro-epileptogenic inflammation and whether these concurrent
processes are co-orchestrated. Identification of regulatory mol-
ecules that govern multiple epileptogenic pathways may allow
for the development of effective preventative therapies.
MicroRNAs (miRNAs) are potent and pleiotropic molecules
with numerous gene targets and conserved across evolution
(Lall et al., 2006; O’Carroll and Schaefer, 2013; Izaurralde,
2015). Their targets include transcription factors and inflamma-
tory cascades (Quinn and O’Neill, 2011; Neo et al., 2014; Su
et al., 2016). Recent studies have found aberrant expression of
miRNAs during epileptogenesis and consequent gene dysregu-
lation, includingmiR-134 (Jimenez-Mateos et al., 2012), miR-128
(Tan et al., 2013), miR-146 (Aronica et al., 2010), and others (Ris-
bud and Porter, 2013; Gorter et al., 2014). Here, we focused on
miR-124 because it is strongly expressed in hippocampus (Smir-
nova et al., 2005), has been linked to NRSF expression in devel-
oping neurons (Conaco et al., 2006; Visvanathan et al., 2007; Yoo
et al., 2009), and has recently been reported to be required for
microglial quiescence (Ponomarev et al., 2011). Using an SE
model of epilepsy generation, we demonstrate that miR-124
plays dual and opposing roles in epileptogenesis. We find that
preventing the SE-provoked reduction of miR-124 levels is
anti-epileptogenic because it prevents increased NRSF expres-
sion and activity. However, preventing reduction in miR-124
levels surprisingly also exacerbates inflammation, with a pro-
epileptogenic effect.
RESULTS
Both Inflammatory and Transcriptional Pathways Are
Activated by an Epilepsy-Promoting Insult
Within hours of SE provoked by the systemic administration of
the glutamate receptor agonist kainic acid (KA) (KA-SE), many
gene networks were activated. First, pro-inflammatory cascadess
Figure 1. Concurrent Induction of Inflam-
matory Mediators and NRSF Expression by
Epilepsy-Provoking Status Epilepticus
(A) Microglia activation in KA-SE rat hippocampus.
Compared with control hippocampus, where the
microglial marker IBA1 is found in wispy ramified
cells, (inset) microglia in KA-SE hippocampus
appear globular (arrowheads). SP, strata pyr-
amidale; SR, strata radiatum. Scale bar, 100 mm.
(B) KA-SE induced mRNA expression of inflam-
matory markers CD11b and pro-inflammatory
cytokines in hippocampus as detected by qPCR.
n = 4 per group.
(C) Representative western blot showing NRSF
protein levels from hippocampal nuclear fractions.
NRSF levels increased at 4 hr following SE and
remained elevated at 48 hr. One hippocampus per
lane; n = 5 animals per time point.
(D) Densitometric analysis of NRSF protein levels
after KA-SE, normalized and compared to control.
(E) qPCR analysis of NRSF mRNA expression in
control hippocampus and following KA-SE shows
upregulation of NRSF compared to control. n = 9
per group.
(F) Repression of NRSF target genes including
HCN1, GRIN2A, and KCC2 at 48 hr post-SE. n = 4
per group.
*p < 0.05. Error bars represent SEM.were induced in the hippocampus evident by microglial activa-
tion, as apparent from the altered microglia morphology from
ramified to globular (Figure 1A), augmented CD11b expression
(Figure 1B), and robust induction of pro-inflammatory cytokines.
Levels of the cytokines interleukin (IL)-1b, IL-6, and tumor necro-
sis factor a (TNF-a), and of IL-1b receptor, were significantly
enhanced, compared with control hippocampus (Figure 1B).
Concurrently, as reported, the transcriptional repressor NRSF
was upregulated at both the mRNA and protein levels already
within 4 hr of KA-SE and remained elevated up to 48 hr (Palm
et al., 1998; McClelland et al., 2011, 2014) (Figures 1C–1E).
Furthermore, NRSF activation by SE led to repression of
NRSF-regulated target genes, including HCN1, GRIN2A, and
KCC2 (Figure 1F).
Hippocampal miR-124 Levels Decline Rapidly following
Epilepsy-Provoking Seizures
As both inflammatory cells and NRSF are induced by SE and
might contribute to epileptogenesis, we sought to identify a po-
tential common upstream regulatory mechanism. However
in silico approaches failed to identify canonical transcriptional
controls common to both. Therefore, we considered non-canon-
ical mechanisms of regulation, including non-coding RNAs, and
focused on miRNAs because they are expressed and function in
all cell types, including neurons and microglia (Ponomarev et al.,
2011; Jovicic et al., 2013;Malmevik et al., 2015). In silico analysis
identified a group of miRNAs predicted to regulate NRSF (Fig-
ure S1A); those reported to regulate neuro-inflammation (Soreq
and Wolf, 2011); and those, such as miR-132, -134, -128, -9,Celland -124 that have been implicated in epilepsy (Jimenez-Mateos
et al., 2012; Kan et al., 2012; Risbud and Porter, 2013). Because
miR-9 and miR-124 also interact with NRSF during neuronal
development (Conaco et al., 2006; Visvanathan et al., 2007;
Yoo et al., 2009), we focused on them.
We found no change in hippocampal miR-9 levels following
KA-SE (Figure S1C). In contrast, miR-124 levels were rapidly
and significantly reduced by 90 min following KA-SE and re-
mained depressed for up to 48 hr (Figure 2A). We then measured
the levels of functional miR-124 by measuring levels bound to
Argonaute 2 (Ago2) within an RNA-induced silencing complex
(RISC). Levels of miR-124 within RISC were lower in KA-SE,
compared to control hippocampi (Figure 2B). This reduction
was selective, because miR-134 RISC levels were increased,
as reported (Jimenez-Mateos et al., 2012) (Figure 2B).
Decreased miR-124 expression was biologically important,
because levels of target mRNAs such as CoREST and AXIN1
were increased (de-repressed) in hippocampus 48 hr after
KA-SE (Figure 2C). To test whether reduced miR-124 in the
RISC complex stemmed from diminished total miR-124 levels
or from potential SE-induced perturbation of miRNA uptake by
RISC, we measured pri-mir-124-1, -2 and -3, precursor mole-
cules expressed from the three genes that code for the same
mature mir-124. pri-mir-124-1 expression was significantly
attenuated after SE (Figure 2D), whereas pri-mir-124-2 and -3
were unaffected (Figure S1D), indicating that reduced mature
miR-124 levels derived from reduced output of the miR-124-1
gene. Together, the findings indicated that the expression, activ-
ity, and function of miR-124 were repressed rapidly following SE,Reports 14, 2402–2412, March 15, 2016 ª2016 The Authors 2403
Figure 2. Reduction of Levels and Function
of miR-124 in Hippocampus following
KA-SE
(A) qPCR analysis of mature miR-124 levels
in control (Ctrl) hippocampus and after KA-SE
miR-124 levels declined as soon as 90 min post-
SE, and this persisted at 48 hr. n = 9 per time point.
(B) Ago2-bound (active) miR-124 levels signifi-
cantly reduced following KA-SE compared with
controls, whereas 134 levels were elevated. n = 5
per group.
(C) qPCR analysis of miR-124 target genes
CoREST and AXIN1. Both miR-124 targets were
de-repressed following KA-SE compared to con-
trols. n = 6 per group.
(D) pri-mir-124-1 expression in hippocampus was
significantly reduced following KA-SE as
compared to controls. n = 6 per time point.
*p < 0.05; #p = 0.07. Error bars represent SEM.preceding the augmentation of inflammatory cytokines and of
NRSF levels.
The miR-124-1 Gene Is Repressed via Histone
Deacetylation that Is Mediated by SIRT1
The aforementioned data demonstrated that KA-SE rapidly
reduced miR-124-1 gene expression, prompting a search for
the underlying mechanisms. Histone deacetylation can take
place within minutes as a result of neuronal activity during mem-
ory processes (Roth et al., 2010; White and Wood, 2014). There-
fore, we probed the deacetylation of chromatin surrounding the
miR-124-1 gene locus as a candidate mechanism for miR-124
repression, and we found enhanced de-acetylation of H4K16
(Figure 3E), which typically denotes gene repression (Ferguson
et al., 2015). Looking for the responsible deacetylating enzyme,
we reasoned that SE represents an extremely metabolically
demanding process (Duffy et al., 1975; Fujikawa et al., 1988;
Carmody and Brennan, 2010; Jupp et al., 2012; Tantama et al.,
2013; Choy et al., 2014). Therefore, we tested for the involvement
of members of the lysine deacetylase family, Sirtuins, which are
activated by changes in cellular energy levels (Blander andGuar-
ente, 2004; Herskovits and Guarente, 2014). KA-SE did not alter
mRNA or total cellular protein levels of SIRT1 (Figures 3A and
3B); however, the levels of SIRT1 within the nuclear fraction of
hippocampal tissue were significantly augmented already at
1 hr post-KA-SE (Figure 3C). (Cytoplasmic levels of SIRT1
were low and did not change appreciably; Figure S2A.)
Augmented nuclear SIRT1 was associated with increased
binding to the miR-124-1 gene promoter (Figure 3D), whereas
binding to miR-124-2 and -3 genes did not change (Figures
S2B and S2C) and reduced H4K16 acetylation (Figure 3E).
Whereas the above data supported that SIRT1 binding caused
the repression of the miR-124-1 gene, we tested this directly
by inhibiting SIRT1, using the specific inhibitor Ex-527. Using2404 Cell Reports 14, 2402–2412, March 15, 2016 ª2016 The Authorsorganotypic hippocampal slice cultures,
we replicated our in vivo findings, dis-
cussed earlier, by treating with KA to
induce seizure-like events (Figures S3Aand S3B). Following 3 hr of seizure-like activity, we applied the
SIRT1 inhibitor and found that this reduced SIRT1 binding
to the chromatin surrounding the miR-124-1 promoter region
(Figure 3F) and prevented deacetylation of the H4K16 locus
(Figure 3G). Inhibition of SIRT1 rescued the expression of pri-
mir-124-1 (Figure 3H), of mature miR-124 (Figure 3I), and of
another established target of SIRT1, miR-134 (Gao et al., 2010)
(Figure S2D). Together, these data indicated that SIRT1 directly
repressed miR-124 by binding to the miR-124-1 gene and de-
acetylating histone lysine residues, promoting the formation of
heterochromatin and consequent gene silencing.
Reduced miR-124 Expression Is Required for Increased
NRSF Expression
miR-124 has been shown to repress microglia activation and the
ensuing inflammatory molecular cascades (Ponomarev et al.,
2011). The relationship between repression of miR-124 and the
expression of NRSF has not been studied in the context of
epileptogenesis. Therefore, having established the link between
epilepsy-promoting metabolic insults such as KA-SE and
repression of miR-124, we asked whether depleted miR-124
was a cause of NRSF upregulation during epileptogenesis
(McClelland et al., 2011, 2014).
To test this possibility, we induced seizure-like events in orga-
notypic hippocampal slice cultures and prevented cellular deple-
tion of miR-124 levels by providing synthetic miRNA (agomir) to a
subgroup of the cultures after termination of seizure-like activity.
Restitution of miR-124 levels abrogated the upregulation of
NRSF expression for up to 96 hr (Figure S3C) and prevented
the repression of NRSF target genes, including GRIN2A (Fig-
ure S3D) (McClelland et al., 2014). The specificity of the effects
of miR-124 was examined by supplementing the medium with
miR-134 agomirs, which did not prevent seizure-induced upre-
gulation of NRSF (Figure S3E).
Figure 3. SIRT1-Mediated Repression of
miR-124 following KA-SE
(A) SIRT1 mRNA expression in hippocampus re-
mains stable after KA-SE. n = 8 per time point. Ctrl,
control.
(B) SIRT1 protein levels, analyzed using western
blot, did not change significantly in whole-cell ex-
tracts obtained from hippocampus from control
and KA-SE rats over a 48-hr time course. n = 3 per
time point.
(C) In contrast, analysis of nuclear fractions from
control and KA-SE hippocampal tissue revealed
significant increase of SIRT1 by 1 hr following SE.
n = 4 per group.
(D) SIRT1 binding to the miR-124-1 gene, analyzed
using ChIP-qPCR, was enhanced significantly
60 min following SE. n = 6 per group. KA repre-
sents KA-SE.
(E) Acetylation levels of H4K16ac, an established
SIRT1 target, were determined by ChIP-qPCR
surrounding the miR-124-1 gene promoter.
H4K16ac levels were reduced in hippocampus of
KA-SE rats compared to controls. n = 4 per group.
(F) Enhanced SIRT1 binding to miR-124-1 gene
promoter after SE was attenuated by SIRT1 inhi-
bition. n = 4 per group.
(G) The SIRT1 inhibitor also abolished SE-induced
H4K16 deacetylation at the miR-124-1 promoter.
ChIP-qPCR quantification of H4K16ac levels in
control and KA-SE groups with vehicle (Veh) or
SIRT1 inhibitor treatment. n = 4 per group.
(H and I) qPCR analysis of pri-mir-124-1 (H) and mature miR-124 (I) expression in control or KA-SE hippocampal slices, after vehicle or SIRT1 inhibition. SIRT1
inhibition prevented repression of pri-miR-124-1 and restored levels of mature miR-124, n = 4 per group.
*p < 0.05; #p = 0.06. Error bars represent SEM.Then, we tested the role of miR-124 in regulating NRSF in vivo.
We infused miR-124 agomirs into the lateral cerebral ventricles
(intracerebroventricularly; i.c.v.) of rats following KA-SE and
measured the mRNA and protein levels of hippocampal NRSF,
using qPCR and western blots, respectively. miR-124 agomirs
prevented seizure-induced upregulation of NRSF at both the
mRNA (Figure 4A) and protein (Figure 4B) levels and prevented
NRSF-mediated repression of GRIN2A (Figure 4C). The com-
bined in vitro and in vivo approaches demonstrated that the rapid
repression of miR-124 levels after prolonged seizures caused
NRSF upregulation and consequent repression of critical
neuronal genes.
miR-124 Regulates NRSF Levels via the Transcription
Factor C/EBPa
In silico analysis revealed no canonical binding site for miR-124
on the 30 UTR of the NRSF mRNA, suggesting the existence of
intermediate miR-124 targets which, in turn, control NRSF
expression. We initially tested a potential role of the miR-124
target PTBP1 (Visvanathan et al., 2007); however, the presence
of increased REST4 splicing (Figure S4B) and no changes in
PTBP1 levels (Figure S4A) suggested alternative regulatory
mechanisms. The robust increase in NRSF mRNA levels pro-
voked by SE suggested that transcriptional mechanisms
were involved. In silico analysis of miR-124 targets combined
with analysis of the NRSF gene, identified transcription factors
that were predicted to both be targets of miR-124 and bind theCellNRSF gene. Among these, the CCAAAT enhancer binding pro-
tein (C/EBPa) has been described as a target of miR-124 that
exerted actions related to microglia regulation (Ponomarev
et al., 2011), and potential C/EBPa binding sites exist within
the NRSF gene promoter (Figure S4C). C/EBPa mRNA and
protein levels increased significantly in the hippocampus of
rats sustaining KA-SE (Figures 4D and 4E), and this increase
was abrogated by administration of miR-124 agomirs immedi-
ately following KA-SE (Figure 4F). Chromatin immunoprecipita-
tion (ChIP) demonstrated that C/EBPa binding to the NRSF
promoter region, but not to the C/EBPa binding site within
the first intron of the NRSF gene (Figure S4D), was significantly
higher in the hippocampus of KA-SE animals compared to
control (Figure 4G). To test whether C/EBPa binding was
required for increased NRSF expression, we blocked C/EBPa
binding by using decoy oligodeoxynucleotides (ODNs)
composed of the C/EBPa binding recognition site (McClelland
et al., 2011). These ODNs, but not scrambled (Scr) ODNs,
decreased C/EBPa binding to the NRSF gene promoter (Fig-
ure 4H). Importantly, blocking C/EBPa binding abrogated upre-
gulation of NRSF following seizure-like activity (Figure 4I).
Together, these data identified C/EBPa as a seizure- and
miR-124-dependent regulator of NRSF expression in hippo-
campus. Specifically, seizure-induced repression of miR-124
levels led to increased levels of C/EBPa, which, in turn,
augmented NRSF expression by binding to the gene promoter
and enhancing transcription.Reports 14, 2402–2412, March 15, 2016 ª2016 The Authors 2405
Figure 4. miR-124 Repression Is Required
for Increased NRSF Expression, and This
Regulation Is Mediated by miR-124 Target
C/EBPa
(A) Hippocampal NRSF mRNA levels in controls
(Ctrl) versus KA-SE (KA) rats given either miR-124
agomir or Scr infusion. Hippocampal NRSF mRNA
levels increased 48 hr following KA-SE + Scr
(KA + Scr), and this increase was blocked in rats
given miR-124 agomirs immediately following SE
(KA + miR-124). n = 6 per group.
(B) NRSF protein levels in nuclear fraction of
hippocampus extracts in control and KA animals
receiving either Scr or miR-124 infusion. NRSF
protein levels were higher in SE + Scr hippocam-
pus 48 hr following insult compared to SE + miR-
124, where levels were comparable to those of
controls. n = 6 per group, one hippocampus per
lane.
(C) miR-124 agomir, but not Scr, treatment pre-
vented seizure-induced NRSF-mediated repres-
sion of GRIN2A; n = 6 per group.
(D) Hippocampal C/EBPa mRNA levels were
enhanced significantly 4 hr following KA-SE and
remained elevated up to 48 hr; n = 8 per time point;
qPCR.
(E) C/EBPa protein levels increased 4 hr post-SE
and remained elevated for at least 48 hr. Repre-
sentative western blot and quantification. n = 5 per
group.
(F) miR-124 agomir treatment following KA-SE
prevented seizure-induced increase of C/EBPa expression compared to KA-SE, which received Scr agomirs; n = 6 per group.
(G) C/EBPa occupancy at NRSF gene increased significantly following KA-SE as compared to controls, n = 6 per group. See Figure S4 for examined binding sites
using ChIP-qPCR.
(H) C/EBPa binding to the NRSF gene after KA seizures was attenuated in hippocampi treated with ordered ODNs, compared to Scr ODN. n = 3 per group.
(I) Inhibition of C/EBPa binding prevented seizure-induced NRSF upregulation. n = 3 per group.
*p < 0.05. Error bars represent SEM. See also Figure S4.Effects of Post-insult miR-124 Replenishment on the
Development of Epilepsy
The aforementioned data suggested that rapid KA-SE-induced
repression of miR-124 levels in hippocampus promotes the
development of epilepsy by two mechanisms: first, miR-124 re-
presses inflammation; therefore, its depletion should promote
increased cytokine expression (Figure 5; Figure S1B). Second,
miR-124 depletion augments NRSF levels implicated in short-
term epileptogenesis (McClelland et al., 2011). Because
these combined data poise miR-124 depletion as an important
upstream mediator of epileptogenesis, we tested whether miR-
124 restitution would prevent epileptogenesis by both prevent-
ing upregulation of NRSF and maintaining quiescent microglia
and preventing inflammation.
We infused miR-124 agomirs or Scr sequences directly into
the brains (i.c.v.) of adult male rats immediately following the
termination of KA-SE. The experimental groups consisted of
rats ‘‘destined’’ to become epileptic (KA-SE with Scr agomirs;
n = 12), rats sustaining KA-SE and treated with miR-124 agomirs
(n = 12), and control rats treated with either Scr agomir or or-
dered miR-124 agomir (n = 5 per group). All rats underwent
continuous 2-month video-electroencephalogram (EEG) moni-
toring (Hellier and Dudek, 2005). We evaluated the presence or
absence of spontaneous seizures (epilepsy), the latency to onset2406 Cell Reports 14, 2402–2412, March 15, 2016 ª2016 The Authorof the first seizure, seizure duration, severity, and the number of
seizures per rat and per group. miR-124 did not influence basal
EEG, including rhythms and amplitude in either controls or
KA-SE rats, and control rats did not develop seizures. The num-
ber of rats developing epilepsy was similar in KA-SE miR-124
agomir and Scr groups (11/12 and 10/12, respectively) (Fig-
ure 5A). Detailed analyses of video-EEG data revealed that the
number of seizures (Figure 5A), average number of seizures
per day (Figure 5B), seizure duration (Figure 5C), seizure severity
on the Racine scale (Racine, 1972) (Figure 5D), and latency to the
onset of the first seizure (Figure 5E) did not distinguish between
groups. Together, these data indicated that administration of
miR-124 agomirs after an epilepsy-provoking insult does not
prevent or modify significantly the disease process.
Unexpected and Complex Actions and Expression
Patterns of miR-124 in the Brain
The lack of effect of miR-124 infusion on epileptogenesis was not
a result of insufficient agomir levels. We used a chemically pro-
tected agomir (see Experimental Procedures), and detected
levels in vivo in ranges comparable to those of endogenous
miR-124 in naive hippocampus (Figure 5F). Additionally, infused
agomirs prevented the SE-induced upregulation of NRSF levels
and activity (Figures 4A–4C). Therefore, we examined whethers
Figure 5. miR-124 Restitution following KA-SE in Rats Does Not
Prevent the Development of Epilepsy
(A) The vast majority (21/24) of KA-SE rats developed epilepsy regardless of
treatment. Blue circles represent individual KA-SE sustaining rats given i.c.v.
miR-124 after the SE, and fuchsia circles represent the Scr agomirs. Total
seizure numbers were similar in both groups.
(B) Average number of seizures per day was not different between rats who
received Scr agomirs and rats who received miR-124 agomirs.
(C) EEG seizure duration was not significantly different between the two
groups.
(D) Seizure severity did not differ significantly between epileptic rats who
received Scr agomir and those who received miR-124 agomirs.
(E) The latency to onset of the first seizure, shown as days from the beginning
of recording (day 2 post-SE) was comparable in both groups.
(F) Hippocampal miR-124 levels in animals who received miR-124 agomirs
following KA-SE (KA), measured using qPCR, were similar to those in naive
controls (Ctrl).
Error bars represent SEM.
Cellrestitution of the SE-depleted miR-124 levels exerted the ex-
pected suppressive actions on SE-induced inflammatory
cascades.
First, we measured the expression of inflammatory markers
and cytokines and found that, as expected, they were elevated
in hippocampi of KA-SE rats compared with controls (Figure 6A)
(Ja¨rvela¨ et al., 2011; Pernot et al., 2011; Vezzani et al., 2011;
Jiang et al., 2013). Unexpectedly, in hippocampi of rats receiving
miR-124 agomirs, cytokine levels were not repressed but
increased (Figure 6A), including IL-1b, TNF-a, and IL-6. A robust
increase in CD11b and modest upregulation of astrocytic GFAP
were also observed after miR-124 infusion (Figure 6A). These
striking effects were not detected in animals which received
Scr agomirs, suggesting specific and surprising pro-inflamma-
tory actions of miR-124.
Then, we examined the cell types influenced by miR-124. We
assessed the four groups described for evidence of inflamma-
tory cell activation using immunocytochemistry (ICC). We
measured the numbers of cells expressing the microglial IBA1
and quantified the proportion of these cells that were activated
(Figures 6B and 6C, inset). While moderate microglia activation
was observed in KA-SE rats (Figures 6B and 6C), in rats that
received miR-124 agomirs, there was a dramatic and unex-
pected activation of microglia not only after KA-SE but also in
control rats given miR-124 (Figures 6B and 6C). The same acti-
vation was not found in control rats given Scr miRNA. Astrocytes
did not seem to be affected by miR-124 agomir infusion, though
they were activated by KA-SE (Figure 6D).
These surprising results suggested that miR-124 and/or
miR-124 agomirs activated rather than repressedmicroglia, pro-
moting inflammation. miR-124 was described in microglia,
where it was considered to have suppressive effects (Pono-
marev et al., 2011), and the findings described earlier might arise
from endogenous or synthetic microglial miR-124. Alternatively,
microglial activation might derive from augmented levels of
endogenous and/or synthetic miR-124 in neurons. To resolve
this question, we examined the cellular localization of both
endogenous and synthetic miR-124 agomirs in hippocampus
(Figure 7). In naive hippocampus, non-radioactive in situ hybrid-
ization (ISH) suggested a neuronal distribution of themiRNA (Fig-
ure 7A). A sense miR-124 probe did not detect any miRNA
expression (Figure 7B). Dual ISH and ICC demonstrated an
exclusive location of the miR-124 in cells expressing the
neuronal marker NeuN and demonstrated lack of co-localization
of miR-124 with cells with the typical features of microglia and
cells expressing the microglial marker IBA1 (Figures 7C and
7D). We used mouse hippocampus in these studies to obviate
potential species differences with published reports. Then, we
examined the cellular distribution of endogenous and synthetic
miR-124 in the same rats used in the current studies. Neuronal
expression of miR-124 was found in controls administered syn-
thetic miRNA (Figures 7E and 7G), as well as in rats infused with
themiR-124 agomir following KA-SE (Figures 7F and 7H). In both
cases, the neuronal nature of cells expressing miR-124 was
identified using NeuN. We did not detect endogenous or syn-
thetic miR-124 in cells co-expressing themicroglial marker IBA1.
Taken together, the data demonstrate that, rather than
reducing brain inflammation, miR-124 led to a profoundReports 14, 2402–2412, March 15, 2016 ª2016 The Authors 2407
Figure 6. miR-124-Induced Inflammatory
Cascades and Microglia Activation
(A) Hippocampal cytokine mRNA levels, including
IL-1b, TNF-a, IL-6, and IL-1 receptor, and CD11b,
were dramatically increased by miR-124, but not
Scr, treatment in control brain. KA-SE (KA)
increased inflammatory markers (including the
astrocytic marker GFAP).
(B and C) ICC and quantification of total and acti-
vated microglia. Insets denote the regions as-
sessed in (C). In control hippocampus, miR124
increased the activation of microglia, assessed as
a transformation of IBA1 cells from thin and rami-
fied into globular cells. (Ctrl-miR124; inset). No
change in total IBA1-expressing cells was noted in
areas CA1, CA3, and the dentate gyrus (DG) hilus.
Microglia activation was not found in control rats
given a Scr agomir (Ctrl + Scr, inset). Moderate
microglia activation was observed in KA-SE rats.
SR, strata radiatum; SP, strata pyramidale.
(D) In contrast to microglia, astrocytes did not
seem to be affected by miR-124 agomir infusion.
As expected, astrocytes were activated by KA-SE.
n = 5 per group.
SR, strata radiatum; SP, strata pyramidale.
*p < 0.05. Error bars represent SEM.activation of microglia, with dramatic increase in the production
of several inflammatory cytokines. These effects of miR-124
were robust enough to negate the mitigating actions of the
miRNA against aberrant upregulation of NRSF. Thus, the combi-
natorial effect of administration of miR-124 after the epilepsy-
inducing insult was a minimal change of the disease process.
However, the mechanisms discovered by the series of experi-
ments described here highlight important actions of miR-124
on neurons and on neuron-glia interactions (Figure S5).
DISCUSSION
The studies described here uncover several aspects of the
mechanisms by which the brain becomes epileptic following
an insult. First, they provide direct molecular links between the
cellular effects of the insult and the disruption of inflammatory
and gene-expression regulatory programs. Second, they high-
light the complex and opposing roles of miR-124 in this disease
process, which likely apply to a number of brain disorders.
Finally, the studies inform us about cell-specific actions of
miR-124 on neuronal and microglia components of the normal
brain.
It has become increasingly clear the acute epileptogenesis,
the process bywhich an insult leads to the development of spon-
taneous seizures, is complex. Roles have been described for
inflammation (Vezzani et al., 2011), as well for a variety of molec-
ular and cellular changes (Brooks-Kayal et al., 2009; Cacheaux
et al., 2009). However, interventions targeting one of these
mechanisms have not been successful in preventing the disease
(Maroso et al., 2011; Jiang et al., 2013; McClelland et al., 2011).
Therefore, here, we sought mechanisms that might regulate
several epilepsy-mediating cellular pathways. We focused on
inflammation as well as on the NRSF pathway. Inflammation ac-
companies and exacerbates epileptogenesis (Dube´ et al., 2010;2408 Cell Reports 14, 2402–2412, March 15, 2016 ª2016 The AuthorVezzani et al., 2011). For NRSF, the repressor’s levels and func-
tion are increased soon after epilepsy-provoking insults. In addi-
tion, a 1-week blockade of NRSF actions reduced significantly
the development of spontaneous seizures for up to 2 weeks,
suggesting that NRSF contributes to the acute epileptogenic
phase. Here, we identified miRNAs—specifically, miR-124 as a
‘‘master-regulator’’ of both inflammation and NRSF—and estab-
lished a direct molecular link between the epileptogenic trigger
(SE) and miR-124.
Epilepsy-Promoting Insults Activate Metabolic Sensors
that Can Modify Gene Expression
Epilepsy-promoting insults, including SE, traumatic brain injury
(TBI), and febrile SE, provoke cellular metabolic stress because
they are either metabolically demanding or constrain nutrient
and oxygen supplies (Duffy et al., 1975; Fujikawa et al., 1988;
Kahles and Brandes, 2012; Sada et al., 2015). Thus, common
cellular pathways for these insults include metabolic derange-
ments, including an altered NAD+/NADH ratio. Here, we find
the rapid activation of the NAD+ sensitive deacetylase SIRT1
following SE. The activation of this potent histone deacetylase
(Imai et al., 2000) causes repression of the miR-124-1 gene
expression via H4K16 deacetylation. It is likely that SE-induced
SIRT1 activity causes repression of other genes and thus repre-
sents a direct mechanism by which epilepsy-promoting insults
rapidly induce large-scale changes in the gene networks.
Notably, SIRT1 inhibition is currently in clinical trials as a treat-
ment for Huntington’s disease (Smith et al., 2014; S€ussmuth
et al., 2015), where repressed levels of miR-124 and NRSF dys-
regulation have been reported (Johnson and Buckley, 2009).
These observations support a commonality in the pathogenesis
of brain disorders, including Huntington’s disease and epilepsy,
based on metabolic dysregulation, SIRT1 activation, and miR-
124 repression.s
Figure 7. miR-124 Resides Exclusively in
Neurons in Mature Mouse and Rat
Hippocampus
(A) Typical neuronal distribution of miR-124 in
naive adult mouse hippocampus visualized
using ISH.
(B) A sense miR-124 probe did not detect any
miRNA expression.
(C) Dual ISH and ICC for IBA1 demonstrated
no cellular co-expression of miR-124 signal
(thin arrows) and microglia (thick arrows).
(D) ISH/ICC miR-124/NeuN demonstrated dually
labeled neurons (arrowheads) as well as neurons
lacking miR-124 (arrow).
(E–H) Distribution of miR-124 in the same rats
used in the present studies. Neuronal (E), but no
microglia (G), expression of miR-124 was found
in controls administered synthetic miRNA, as well
as in rats infused with the miR-124 agomir
following KA-SE (F and H). Arrowheads indicate
co-expression of miR-124 andNeuN. Thick arrows
delineate delicate ramified microglia in controls (G)
and globular/amoeboid microglia in KA-SE hip-
pocampus. n = 3 per group.
Scale bars, 100 mm.miR-124: A Prevalent miRNA with Unexpected Actions
on Microglia
Aberrant miRNA expression and function influence numerous
and diverse molecular and cellular cascades (Lall et al., 2006;
Makeyev et al., 2007). Here, we provide the evidence for the
role of rapid depletion of miR-124 in the aberrant upregulation
of NRSF, reported for a number of brain insults (Calderone
et al., 2003; Zuccato et al., 2007; Doeppner et al., 2013). This is
mediated by the miR-124 target transcription factor C/EBPa.
Whereas this transcription factor has yet to be studied in in the
context of epilepsy, othermembers of theC/CAAT enhancer pro-
tein are activated bySE (Engel et al., 2013b; Brennan et al., 2015).
miR-124, in addition to modulating neuronal phenotype via
protean changes in gene expression, is implicated in microglial
function. Specifically, reduced miR-124 levels in microglia
caused their activation (Ponomarev et al., 2011). Thus, in view
of the crucial roles for CNS glial cells and their production of in-Cell Reports 14, 2402–2412flammatory molecules in insult-provoked
epilepsy, we considered a second,micro-
glial-mediated anti-epileptogenic func-
tion of miR-124. Surprisingly, prevention
of miR-124 depletion in hippocampus
provoked robust microglial activation
and striking augmentation of pro-inflam-
matory cytokine expression including IL-
1b (Maroso et al., 2011).
Basis of the Surprising Effects of
miR-124 on Microglia
These unexpected findings were not a
result of non-specific or toxic actions of
the synthetic miR-124. We used a chem-
ically protected agomir to provide stabilityin vivo, so it was conceivable that the modification might induce
an inflammatory response. However, the samemodification was
present in the random/Scr control RNA, which did not induce
inflammation. The miR-124 dose used in this study did not
lead to overt toxicity, and no animals died or appeared ill for
the 2-month duration of the study. Importantly, the effects of
the miR-124 agomir were selective to microglia: NeuN-stained
neurons appeared healthy, and astrocytes were unaffected.
These data suggested that the synthetic miR-124 was not toxic
but rather recapitulated the actions of endogenous miRNA.
Then, howmight endogenous and synthetic miR-124 promote
the activation of microglia? The most straightforward mecha-
nisms involve the intrinsic function of miRNAs in cells where
they are produced. Therefore, we examined the cell types
harboring endogenous miR-124, as well as the synthetic agomir.
We detected miR-124 in NeuN-expressing neurons in adult
mouse and rat hippocampi but failed to detect miR-124 in, March 15, 2016 ª2016 The Authors 2409
IBA1-expressing microglia. This was the case in naive hippo-
campus as well as following KA-SE. These findings strongly sug-
gested that, in rodent hippocampus, miR-124 was expressed
exclusively in neurons. In addition, in hippocampi of rats given
synthetic miR-124, we were unable to detect any miR-124
(endogenous or agomir) in microglia. It is conceivable that the di-
goxigenin (DIG)-labeled ISH probes did not bind the modified
miR-124 agomirs due to steric hindrance, and miR-124 agomirs
were taken up by microglia. This possibility does not influence
the conclusion that endogenous miR-124 is located in—and,
therefore, acts within—neurons. Notably, our results, using ISH
combined with ICC are in close accord with a recently published
study (A˚kerblom et al., 2012) utilizing a transgenic approach. This
study used a mouse expressing GFP modified to contain miR-
124-binding sites in its mRNA. If miR-124 and GFP were ex-
pressed in the same cell, then miR-124 should inhibit GFP
expression. A˚kerblom et al. failed to detect microglia lacking
GFP expression, whereas all neurons lacked GFP expression,
indicating that miR-124 was confined to neurons. Whereas
both our study and A˚kerblom et al.’s study used rigorous sin-
gle-cell resolution in situ approaches, microglial miR-124 was
previously reported based on fluorescence-activated cell sorting
(FACS), using cellular profiles (Ponomarev et al., 2011). Poten-
tially, technical challenges in obtaining pure microglial cell pop-
ulations might account for the apparent miR-124 expression in
microglia using FACS.
Its neuronal localization suggests that both endogenous and
synthetic miR-124 activate microglia via neuronal-microglia
signaling. A plausible mechanism involves repressing target
mRNAs such as Co-REST (Baudet et al., 2011), important for
the regulation of necrosis factor kB (NF-kB) (Saijo et al., 2009).
Whereas both neuronal and glial mechanisms will require future
study, the fundamental discoveries here are that miR-124 is neu-
ronally expressed and that it exerts pro-inflammatory functions in
epileptogenesis. Indeed, reduced miR-124 expression following
SE may be an adaptive response, aiming to curb excessive
inflammation in the brain and limit its potential adverse effects
on neuronal survival (Maroso et al., 2011; Vezzani et al., 2011).
In the context of the generation of neurological diseases such
as epilepsy (and potentially others), the activation of microglia
and inflammation bymiR-124 counterbalanced disease-prevent-
ing effects throughNRSF inhibition. Thus,miR-124plays a pivotal
role in epileptogenesis, albeit viadual andopposingmechanisms.EXPERIMENTAL PROCEDURES
For more details regarding the materials and methods used in this study,
please see the Supplemental Experimental Procedures.
All experiments were approved by the University of California, Irvine, Institu-
tional Animal Care and Use Committee and conformed to NIH guidelines.
Animals
Adult male Sprague-Dawley rats were housed under a 12-hr:12-hr light:dark
cycle, with ad libitum access to food and water.
Surgery, Induction of Status Epilepticus, and miR-124 Agomir
Treatment In Vivo
Rats (control + Scr, n = 5; control + miR124 agomir, n = 5; KA + Scr, n = 12;
KA + miR124 agomir, n = 12) were implanted with cannula and bilateral hippo-2410 Cell Reports 14, 2402–2412, March 15, 2016 ª2016 The Authorcampal electrodes as reported elsewhere (Dube´ et al., 2010), and as described
in the Supplemental Experimental Procedures.
ChIP
ChIP was performed as previously described (McClelland et al., 2011) and
delineated in the Supplemental Experimental Procedures.
Ago2 IP
Ago2 IP was performed as described by Schratt et al. (2006). Briefly, hippo-
campi were solubilized in immunoprecipitation (IP) buffer (300 mM NaCl,
5 mM MgCl2, 0.1% NP-40, 50 mM Tris-HCl) and centrifuged. 400 ml superna-
tant was incubated overnight with 5 mg of either Ago2 antibody (C34C6) or rab-
bit immunoglobulin G (IgG). Protein A agarose beads were added at 4C on a
rotator, samples were then centrifuged, and the supernatant was removed.
Beads were washed and processed for miRNA analysis using qRT-PCR.
Ago2-bound miRNAs were normalized to RNU6B.
ISH and Combined ISH/ICC
ISH and combined ISH/ICC were performed as reported previously (Noam
et al., 2012) and detailed in the Supplemental Experimental Procedures. To
detect miR-124, DIG-30-conjugated miR124 sense and antisense oligonucleo-
tide probes were generated. Specificity of hybridization was verified by
substituting labeled sense for the antisense probe and by omitting the anti-
sense probe or alkaline-phosphatase-conjugated antibody. For combined
ISH/ICC, free-floating sections were first processed for ISH and then pro-
cessed for ICC.
Statistical Analyses
All analyses were performed without knowledge of treatment group. Standard
t test was used to compare two groups; for analyses involving more than two
groups, one-way or two-way ANOVA was used. Statistical significance was
set at p < 0.05. Experiments were repeated at least twice.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and two tables and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2016.02.042.
AUTHOR CONTRIBUTIONS
Conceptualization: G.P.B. and T.Z.B.; Methodology and Investigation: G.P.B.,
D.D., Y.C., K.P.P., E.J.M., A.M.H., C.M.D., and Y.-T.M.; Writing – Original
Draft: G.P.B. and T.Z.B.; Writing – Review and Editing: G.P.B. and T.Z.B.;
Funding Acquisition: G.P.B. and T.Z.B.; Resources: T.Z.B.; Supervision: T.Z.B.
ACKNOWLEDGMENTS
We would like to thank Pam See for technical support and Dr. Black for the
PTBP1 antibody. This work was supported by NIH grants R37 NS35439,
T32 NS45540, and R01 NS78279 and The George Hewitt Foundation for
Biomedical Research (to G.P.B.).
Received: January 29, 2015
Revised: December 22, 2015
Accepted: February 4, 2016
Published: March 3, 2016
REFERENCES
A˚kerblom, M., Sachdeva, R., Barde, I., Verp, S., Gentner, B., Trono, D., and
Jakobsson, J. (2012). MicroRNA-124 is a subventricular zone neuronal fate
determinant. J. Neurosci. 32, 8879–8889.
Aronica, E., Fluiter, K., Iyer, A., Zurolo, E., Vreijling, J., van Vliet, E.A., Baayen,
J.C., and Gorter, J.A. (2010). Expression pattern of miR-146a, ans
inflammation-associated microRNA, in experimental and human temporal
lobe epilepsy. Eur. J. Neurosci. 31, 1100–1107.
Baldelli, P., and Meldolesi, J. (2015). The transcription repressor REST in adult
neurons: physiology, pathology, and diseases. eNeuro 2, 10.1523.
Baudet, M.L., Zivraj, K.H., Abreu-Goodger, C., Muldal, A., Armisen, J., Blen-
kiron, C., Goldstein, L.D., Miska, E.A., and Holt, C.E. (2011). miR-124 acts
through CoREST to control onset of Sema3A sensitivity in navigating retinal
growth cones. Nat. Neurosci. 15, 29–38.
Blander, G., and Guarente, L. (2004). The Sir2 family of protein deacetylases.
Annu. Rev. Biochem. 73, 417–435.
Brennan, G.P., Jimenez-Mateos, E.M., Sanz-Rodriguez, A., Mooney, C.M.,
Tzivion, G., Henshall, D.C., and Engel, T. (2015). Overexpression of 14-3-3z In-
creases Brain Levels of C/EBP Homologous Protein CHOP. J. Mol. Neurosci.
56, 255–262.
Brooks-Kayal, A.R., Raol, Y.H., and Russek, S.J. (2009). Alteration of epilepto-
genesis genes. Neurotherapeutics 6, 312–318.
Cacheaux, L.P., Ivens, S., David, Y., Lakhter, A.J., Bar-Klein, G., Shapira, M.,
Heinemann, U., Friedman, A., and Kaufer, D. (2009). Transcriptome profiling
reveals TGF-beta signaling involvement in epileptogenesis. J. Neurosci. 29,
8927–8935.
Calderone, A., Jover, T., Noh, K.M., Tanaka, H., Yokota, H., Lin, Y., Grooms,
S.Y., Regis, R., Bennett, M.V., and Zukin, R.S. (2003). Ischemic insults dere-
press the gene silencer REST in neurons destined to die. J. Neurosci. 23,
2112–2121.
Carmody, S., and Brennan, L. (2010). Effects of pentylenetetrazole-induced
seizures on metabolomic profiles of rat brain. Neurochem. Int. 56, 340–344.
Choy, M., Dube´, C.M., Patterson, K., Barnes, S.R., Maras, P., Blood, A.B.,
Hasso, A.N., Obenaus, A., and Baram, T.Z. (2014). A novel, noninvasive, pre-
dictive epilepsy biomarker with clinical potential. J. Neurosci. 34, 8672–8684.
Conaco, C., Otto, S., Han, J.J., and Mandel, G. (2006). Reciprocal actions of
REST and a microRNA promote neuronal identity. Proc. Natl. Acad. Sci.
USA 103, 2422–2427.
Doeppner, T.R., Doehring, M., Bretschneider, E., Zechariah, A., Kaltwasser,
B., M€uller, B., Koch, J.C., Ba¨hr, M., Hermann, D.M., and Michel, U. (2013).
MicroRNA-124 protects against focal cerebral ischemia via mechanisms
involving Usp14-dependent REST degradation. Acta Neuropathol. 126,
251–265.
Dube´, C.M., Ravizza, T., Hamamura, M., Zha, Q., Keebaugh, A., Fok, K.,
Andres, A.L., Nalcioglu, O., Obenaus, A., Vezzani, A., and Baram, T.Z.
(2010). Epileptogenesis provoked by prolonged experimental febrile seizures:
mechanisms and biomarkers. J. Neurosci. 30, 7484–7494.
Duffy, T.E., Howse, D.C., and Plum, F. (1975). Cerebral energy metabolism
during experimental status epilepticus. J. Neurochem. 24, 925–934.
Engel, J., Jr., Thompson, P.M., Stern, J.M., Staba, R.J., Bragin, A., and Mody,
I. (2013a). Connectomics and epilepsy. Curr. Opin. Neurol. 26, 186–194.
Engel, T., Sanz-Rodgriguez, A., Jimenez-Mateos, E.M., Concannon, C.G.,
Jimenez-Pacheco, A., Moran, C., Mesuret, G., Petit, E., Delanty, N., Farrell,
M.A., et al. (2013b). CHOP regulates the p53-MDM2 axis and is required for
neuronal survival after seizures. Brain 136, 577–592.
Ferguson, D., Shao, N., Heller, E., Feng, J., Neve, R., Kim, H.D., Call, T., Mag-
azu, S., Shen, L., and Nestler, E.J. (2015). SIRT1-FOXO3a regulate cocaine ac-
tions in the nucleus accumbens. J. Neurosci. 35, 3100–3111.
Fujikawa, D.G., Vannucci, R.C., Dwyer, B.E., and Wasterlain, C.G. (1988).
Generalized seizures deplete brain energy reserves in normoxemic newborn
monkeys. Brain Res. 454, 51–59.
Gao, J.,Wang,W.Y., Mao, Y.W., Gra¨ff, J., Guan, J.S., Pan, L., Mak, G., Kim, D.,
Su, S.C., and Tsai, L.H. (2010). A novel pathway regulates memory and plas-
ticity via SIRT1 and miR-134. Nature 466, 1105–1109.
Gao, Z., Ure, K., Ding, P., Nashaat, M., Yuan, L., Ma, J., Hammer, R.E., and
Hsieh, J. (2011). The master negative regulator REST/NRSF controls adult
neurogenesis by restraining the neurogenic program in quiescent stem cells.
J. Neurosci. 31, 9772–9786.CellGoldberg, E.M., and Coulter, D.A. (2013). Mechanisms of epileptogenesis: a
convergence on neural circuit dysfunction. Nat. Rev. Neurosci. 14, 337–349.
Gorter, J.A., Iyer, A., White, I., Colzi, A., van Vliet, E.A., Sisodiya, S., and Aron-
ica, E. (2014). Hippocampal subregion-specific microRNA expression during
epileptogenesis in experimental temporal lobe epilepsy. Neurobiol. Dis. 62,
508–520.
Hellier, J.L., and Dudek, F.E. (2005). Chemoconvulsant model of chronic spon-
taneous seizures. Curr. Protoc. Neurosci. Chapter 9, Unit 9.19.
Herskovits, A.Z., and Guarente, L. (2014). SIRT1 in neurodevelopment and
brain senescence. Neuron 81, 471–483.
Imai, S., Armstrong, C.M., Kaeberlein, M., and Guarente, L. (2000). Transcrip-
tional silencing and longevity protein Sir2 is an NAD-dependent histone deace-
tylase. Nature 403, 795–800.
Izaurralde, E. (2015). GENE REGULATION. Breakers and blockers—miRNAs
at work. Science 349, 380–382.
Ja¨rvela¨, J.T., Lopez-Picon, F.R., Plysjuk, A., Ruohonen, S., and Holopainen,
I.E. (2011). Temporal profiles of age-dependent changes in cytokine mRNA
expression and glial cell activation after status epilepticus in postnatal rat hip-
pocampus. J. Neuroinflammation 8, 29.
Jiang, J., Quan, Y., Ganesh, T., Pouliot, W.A., Dudek, F.E., and Dingledine, R.
(2013). Inhibition of the prostaglandin receptor EP2 following status epilepticus
reduces delayed mortality and brain inflammation. Proc. Natl. Acad. Sci. USA
110, 3591–3596.
Jimenez-Mateos, E.M., Engel, T., Merino-Serrais, P., McKiernan, R.C.,
Tanaka, K., Mouri, G., Sano, T., O’Tuathaigh, C., Waddington, J.L., Prenter,
S., et al. (2012). Silencing microRNA-134 produces neuroprotective and
prolonged seizure-suppressive effects. Nat. Med. 18, 1087–1094.
Johnson, R., and Buckley, N.J. (2009). Gene dysregulation in Huntington’s
disease: REST, microRNAs and beyond. Neuromolecular Med. 11, 183–199.
Jovicic, A., Roshan, R., Moisoi, N., Pradervand, S., Moser, R., Pillai, B., and
Luthi-Carter, R. (2013). Comprehensive expression analyses of neural cell-
type-specificmiRNAs identify new determinants of the specification andmain-
tenance of neuronal phenotypes. J. Neurosci. 33, 5127–5137.
Jupp, B., Williams, J., Binns, D., Hicks, R.J., Cardamone, L., Jones, N., Rees,
S., and O’Brien, T.J. (2012). Hypometabolism precedes limbic atrophy and
spontaneous recurrent seizures in a rat model of TLE. Epilepsia 53, 1233–
1244.
Kahles, T., and Brandes, R.P. (2012). NADPH oxidases as therapeutic targets
in ischemic stroke. Cell. Mol. Life Sci. 69, 2345–2363.
Kan, A.A., van Erp, S., Derijck, A.A., de Wit, M., Hessel, E.V., O’Duibhir, E., de
Jager, W., Van Rijen, P.C., Gosselaar, P.H., de Graan, P.N., and Pasterkamp,
R.J. (2012). Genome-wide microRNA profiling of human temporal lobe epi-
lepsy identifies modulators of the immune response. Cell. Mol. Life Sci. 69,
3127–3145.
Lall, S., Gr€un, D., Krek, A., Chen, K., Wang, Y.L., Dewey, C.N., Sood, P.,
Colombo, T., Bray, N., Macmenamin, P., et al. (2006). A genome-wide map
of conserved microRNA targets in C. elegans. Curr. Biol. 16, 460–471.
Li, Z., Li, B., Zhu, X., Yin, P., Liu, J., Huang, S., and Sun, R. (2013). Neuropro-
tective effects of anti-high-mobility group box 1 antibody in juvenile rat
hippocampus after kainic acid-induced status epilepticus. Neuroreport 24,
785–790.
Makeyev, E.V., Zhang, J., Carrasco, M.A., and Maniatis, T. (2007). The
MicroRNA miR-124 promotes neuronal differentiation by triggering brain-
specific alternative pre-mRNA splicing. Mol. Cell 27, 435–448.
Malmevik, J., Petri, R., Klussendorf, T., Knauff, P., A˚kerblom, M., Johansson,
J., Soneji, S., and Jakobsson, J. (2015). Identification of the miRNA targetome
in hippocampal neurons using RIP-seq. Sci. Rep. 5, 12609.
Maroso, M., Balosso, S., Ravizza, T., Liu, J., Bianchi, M.E., and Vezzani, A.
(2011). Interleukin-1 type 1 receptor/Toll-like receptor signalling in epilepsy:
the importance of IL-1beta and high-mobility group box 1. J. Intern. Med.
270, 319–326.
McClelland, S., Flynn, C., Dube´, C., Richichi, C., Zha, Q., Ghestem, A.,
Esclapez, M., Bernard, C., and Baram, T.Z. (2011). Neuron-restrictive silencerReports 14, 2402–2412, March 15, 2016 ª2016 The Authors 2411
factor-mediated hyperpolarization-activated cyclic nucleotide gated channel-
opathy in experimental temporal lobe epilepsy. Ann. Neurol. 70, 454–464.
McClelland, S., Brennan, G.P., Dube´, C., Rajpara, S., Iyer, S., Richichi, C.,
Bernard, C., and Baram, T.Z. (2014). The transcription factor NRSF contributes
to epileptogenesis by selective repression of a subset of target genes. eLife 3,
e01267.
Neo, W.H., Yap, K., Lee, S.H., Looi, L.S., Khandelia, P., Neo, S.X., Makeyev,
E.V., and Su, I.H. (2014). MicroRNA miR-124 controls the choice between
neuronal and astrocyte differentiation by fine-tuning Ezh2 expression.
J. Biol. Chem. 289, 20788–20801.
Noam, Y., Phan, L., McClelland, S., Manders, E.M., Ehrengruber, M.U.,
Wadman,W.J., Baram, T.Z., and Chen, Y. (2012). Distinct regional and subcel-
lular localization of the actin binding protein filam-A in the mature rat brain.
J Comp Neurol. 520, 3013–3034.
O’Carroll, D., and Schaefer, A. (2013). General principals of miRNA biogenesis
and regulation in the brain. Neuropsychopharmacology 38, 39–54.
Palm, K., Belluardo, N., Metsis, M., and Timmusk, T. (1998). Neuronal expres-
sion of zinc finger transcription factor REST/NRSF/XBR gene. J. Neurosci. 18,
1280–1296.
Pernot, F., Heinrich, C., Barbier, L., Peinnequin, A., Carpentier, P., Dhote, F.,
Baille, V., Beaup, C., Depaulis, A., and Dorandeu, F. (2011). Inflammatory
changes during epileptogenesis and spontaneous seizures in a mouse model
of mesiotemporal lobe epilepsy. Epilepsia 52, 2315–2325.
Ponomarev, E.D., Veremeyko, T., Barteneva, N., Krichevsky, A.M., and
Weiner, H.L. (2011). MicroRNA-124 promotes microglia quiescence and sup-
presses EAE by deactivating macrophages via the C/EBP-a-PU.1 pathway.
Nat. Med. 17, 64–70.
Quinn, S.R., and O’Neill, L.A. (2011). A trio of microRNAs that control Toll-like
receptor signalling. Int. Immunol. 23, 421–425.
Racine, R.J. (1972). Modification of seizure activity by electrical stimulation. I.
After-discharge threshold. Electroencephalogr. Clin. Neurophysiol. 32,
269–279.
Risbud, R.M., and Porter, B.E. (2013). Changes in microRNA expression in the
whole hippocampus and hippocampal synaptoneurosome fraction following
pilocarpine induced status epilepticus. PLoS ONE 8, e53464.
Rossignol, E., Kobow, K., Simonato, M., Loeb, J.A., Grisar, T., Gilby, K.L.,
Vinet, J., Kadam, S.D., and Becker, A.J. (2014). WONOEP appraisal: new ge-
netic approaches to study epilepsy. Epilepsia 55, 1170–1186.
Roth, T.L., Roth, E.D., and Sweatt, J.D. (2010). Epigenetic regulation of genes
in learning and memory. Essays Biochem. 48, 263–274.
Sada, N., Lee, S., Katsu, T., Otsuki, T., and Inoue, T. (2015). Epilepsy treat-
ment. Targeting LDH enzymes with a stiripentol analog to treat epilepsy. Sci-
ence 347, 1362–1367.
Saijo, K., Winner, B., Carson, C.T., Collier, J.G., Boyer, L., Rosenfeld, M.G.,
Gage, F.H., and Glass, C.K. (2009). A Nurr1/CoREST pathway in microglia
and astrocytes protects dopaminergic neurons from inflammation-induced
death. Cell 137, 47–59.2412 Cell Reports 14, 2402–2412, March 15, 2016 ª2016 The AuthorSchratt, G.M., Tuebing, F., Nigh, E.A., Kane, C.G., Sabatini, M.E., Kiebler, M.,
and Greenberg, M.E. (2006). A brain-specific microRNA regulates dendritic
spine development. Nature 439, 283–289.
Simonato, M., Brooks-Kayal, A.R., Engel, J., Jr., Galanopoulou, A.S., Jensen,
F.E., Moshe´, S.L., O’Brien, T.J., Pitkanen, A., Wilcox, K.S., and French, J.A.
(2014). The challenge and promise of anti-epileptic therapy development in an-
imal models. Lancet Neurol. 13, 949–960.
Smirnova, L., Gra¨fe, A., Seiler, A., Schumacher, S., Nitsch, R., and Wulczyn,
F.G. (2005). Regulation of miRNA expression during neural cell specification.
Eur. J. Neurosci. 21, 1469–1477.
Smith, M.R., Syed, A., Lukacsovich, T., Purcell, J., Barbaro, B.A., Worthge,
S.A., Wei, S.R., Pollio, G., Magnoni, L., Scali, C., et al. (2014). A potent and se-
lective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models
of Huntington’s disease. Hum. Mol. Genet. 23, 2995–3007.
Soreq, H., and Wolf, Y. (2011). NeurimmiRs: microRNAs in the neuroimmune
interface. Trends Mol. Med. 17, 548–555.
Su,W., Aloi, M.S., andGarden, G.A. (2016). MicroRNAsmediating CNS inflam-
mation: Small regulators with powerful potential. Brain Behav. Immun. 52, 1–8.
S€ussmuth, S.D., Haider, S., Landwehrmeyer, G.B., Farmer, R., Frost, C.,
Tripepi, G., Andersen, C.A., Di Bacco, M., Lamanna, C., Diodato, E., et al.;
PADDINGTON Consortium (2015). An exploratory double-blind, randomized
clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington’s
disease. Br. J. Clin. Pharmacol. 79, 465–476.
Tan, C.L., Plotkin, J.L., Venø, M.T., von Schimmelmann, M., Feinberg, P.,
Mann, S., Handler, A., Kjems, J., Surmeier, D.J., O’Carroll, D., et al. (2013).
MicroRNA-128 governs neuronal excitability and motor behavior in mice. Sci-
ence 342, 1254–1258.
Tantama, M., Martinez-Francois, J.R., Mongeon, R., and Yellen, G. (2013).
Imaging energy status in live cells with a fluorescent biosensor of the intracel-
lular ATP-to-ADP ratio. Nat. Comm. 4, 2550.
Vezzani, A., French, J., Bartfai, T., and Baram, T.Z. (2011). The role of inflam-
mation in epilepsy. Nat. Rev. Neurol. 7, 31–40.
Visvanathan, J., Lee, S., Lee, B., Lee, J.W., and Lee, S.K. (2007). The micro-
RNAmiR-124 antagonizes the anti-neural REST/SCP1 pathway during embry-
onic CNS development. Genes Dev. 21, 744–749.
White, A.O., and Wood, M.A. (2014). Does stress remove the HDAC brakes
for the formation and persistence of long-term memory? Neurobiol. Learn.
Mem. 112, 61–67.
Yoo, A.S., Staahl, B.T., Chen, L., and Crabtree, G.R. (2009). MicroRNA-medi-
ated switching of chromatin-remodelling complexes in neural development.
Nature 460, 642–646.
Zuccato, C., Belyaev, N., Conforti, P., Ooi, L., Tartari, M., Papadimou, E.,
MacDonald, M., Fossale, E., Zeitlin, S., Buckley, N., and Cattaneo, E. (2007).
Widespread disruption of repressor element-1 silencing transcription factor/
neuron-restrictive silencer factor occupancy at its target genes in Huntington’s
disease. J. Neurosci. 27, 6972–6983.s
